
Ferring Pharmaceuticals is a global company that specializes in developing and manufacturing medicines for rare and specialty diseases. They focus on conditions that affect the reproductive and gastroenterological systems.
Ferring Pharmaceuticals has a portfolio of over 30 products, including treatments for conditions such as gastroparesis and hypogonadism. These products are available in over 100 countries worldwide.
Their medications are designed to address the unique needs of patients with rare and specialty diseases, often offering new treatment options that were previously unavailable.
Broaden your view: Indian Rare Earths
Ferring Pharmaceuticals Products
Ferring Pharmaceuticals has a diverse portfolio of products that cater to various medical needs. One of the company's key areas of focus is reproductive health, where products like Triptorelin, Menopur, and Propess are used to treat conditions such as infertility and induce labor.
In the field of gastroenterology, Ferring's products like Pentasa and Picoprep are used to treat inflammatory bowel disease and clean the bowel, respectively. The company's portfolio also includes products for urology, such as Degarelix, which is used to treat prostate cancer.
Here are some of Ferring's notable products in various therapeutic areas:
Ferring's products also include Minirin, which is used to treat bedwetting in children and nocturia in adults, and Euflexxa, which is used to treat osteoarthritis of the knee.
Reproductive Medicine & Maternal Health
Ferring Pharmaceuticals offers a range of products for reproductive medicine and maternal health, making it a trusted partner for healthcare professionals and patients alike.
Their products include Gonapeptyl/Decapeptyl, a gonadotropin-releasing hormone (GnRH) agonist used to treat conditions such as prostate cancer and precocious puberty.
Ferring's reproductive medicine portfolio also includes Menopur/Menogon/Repronex, an ovarian-stimulating treatment used in the preparation for in vitro fertilization.
In addition to these products, Ferring offers Propess, a vaginal insert containing dinoprostone, used to initiate cervical ripening in patients at term.
Their products are used in various reproductive health applications, including fertility treatment, menopause management, and obstetric care.
Here's a list of some of the reproductive medicine and maternal health products offered by Ferring Pharmaceuticals:
- Triptorelin (Gonapeptyl/Decapeptyl)
- Menopur/Menogon/Repronex (HP-hMG)
- Propess (dinoprostone)
- Endometrin/Lutinus (progesterone)
- Tractocile (atosiban)
- Pabal/Duratocin/Lonactene/Duratobal (carbetocin)
- Choragon/Brevactid (u-hCG)
- Lutrepulse/Lutrelef (gonadorelin acetate)
- Norprolac (quinagolide hydrochloride)
- Rekovelle (follitropin delta)
Firmagon (Degarelix)
Firmagon (Degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It works by decreasing testosterone levels, which causes the cancer cells to die and reduces the size of the tumour.
This treatment has a novel mechanism of action that differs from traditional LHRH agonist therapy commonly used. It's a unique approach that's effective in managing prostate cancer.
Firmagon has been approved in 74 countries, providing access to this treatment for many patients worldwide.
Norprolac (Quinagolide Hydrochloride)

Norprolac (Quinagolide Hydrochloride) is a selective, D2 dopamine agonist used for the treatment of elevated levels of prolactin.
The secretion of prolactin is reduced by the neurotransmitter dopamine, which acts on prolactin-secreting cells in the pituitary gland.
NORPROLAC mimics the action of dopamine in the pituitary to reduce prolactin levels.
NORPROLAC is provided in tablet form for oral administration.
Nocdurna (Desmopressin)
Nocdurna (Desmopressin) is a medication used to treat nocturia in adults. It's a complex medical condition that affects millions of people worldwide.
The medication works by reducing the night-time production of urine, which is responsible for nocturia in up to 88% of cases. Nocturia is the need to awaken at night to pass urine.
NOCDURNA is available in once-daily lyophilisate tablets that are administered sublingually. This means they're placed under the tongue and dissolve, releasing the medication without the need for water.
The tablets come in gender-specific low doses, tailored specifically for men (50 mcg) and women (25 mcg). This ensures the medication is effective while minimizing potential side effects.
Ferring Pharmaceuticals, the manufacturer of NOCDURNA, is committed to ensuring their medicines meet the highest quality standards. They've taken steps to address quality control issues with other desmopressin products, including a voluntary global recall of certain nasal sprays.
If you're experiencing nocturia and are interested in learning more about NOCDURNA, it's best to consult with your treating physician. They can discuss potential treatment options and help you determine if NOCDURNA is right for you.
You might enjoy: Quality Chemical Industries Limited
Regulatory Updates
Ferring Pharmaceuticals has resumed shipments of Menopur in the United States and other countries after a temporary suspension due to changes in the manufacturing process. Data reviewed by Ferring indicates that the safety and efficacy of the product remains unaltered.
Ferring Pharmaceuticals has also issued a voluntary global recall of certain products, including Minirin, Octostim, DDAVP, and Stimate nasal sprays, due to out-of-specification results during testing. New machinery has been commissioned and a variation application submitted to the European regulatory authorities to resolve this issue.
Ferring Pharmaceuticals holds import registrations or U.S. agent authorizations with organizations such as Ferring International Center SA and Brenda Marczi.
Updated Statement on Minirin Desmopressin Nasal Spray
Ferring Pharmaceuticals has issued an updated statement regarding Minirin Desmopressin Nasal Spray. In 2020, they initiated a precautionary voluntary global recall of all batches of the product due to out-of-specification results during testing.
The affected products include Minirin (desmopressin) Nasal Spray 0.1 mg/ml room temperature stable (RTS) formulation, Octostim (desmopressin) Nasal Spray 1.5 mg/ml, DDAVP (desmopressin acetate, 10 mcg/0.1 mL), Stimate (desmopressin acetate, 1.5 mg/1 mL) Nasal Spray, and Generic Desmopressin Acetate (10 mcg/0.1mL) Nasal Spray.
Ferring has commissioned new machinery to resolve the issue and submitted a variation application to the European regulatory authorities on November 28th, 2024. Submission to the US regulatory authorities is planned for Q2-2025.
Ferring is committed to ensuring that their medicines adhere to the highest quality standards for their patients, and to working with health authorities to ensure alternatives for patients. Any patients or caregivers with concerns or questions about treatment alternatives should immediately contact their treating physician.

The company is working diligently to resolve the issue and get their products back on the market as soon as possible. This includes collaborating with regulatory authorities to ensure that their products meet the necessary standards.
Ferring Pharmaceuticals Inc. is a global pharmaceutical company with import registrations or U.S. agent authorizations in conjunction with Ferring International Center SA and Brenda Marczi.
Legal Procedures Against
Ferring Pharmaceuticals has been involved in a class action lawsuit regarding their Bravelle product, which was recalled in 2015 after tests revealed it wasn't as effective as claimed, putting women's health at risk.
The company distributed a modified version of the "De Simone formula", a probiotic formulation invented by Professor Claudio de Simone in the early 1990s.
A class action was filed against Ferring Pharmaceuticals in 2016 for their handling of the Bravelle product.
The "De Simone formula" was the subject of several clinical tests, which demonstrated its effectiveness in treating certain diseases.
Ferring Pharmaceuticals is currently in a legal battle with Professor Claudio de Simone over the distribution of the modified formula under the name VSL#3.
Company Information

Ferring Pharmaceuticals is a privately-held company. It was founded in 1950 by a Swiss entrepreneur.
The company is headquartered in Saint-Prex, Switzerland. Ferring Pharmaceuticals is a global biopharmaceutical company.
Ferring Pharmaceuticals focuses on developing treatments for rare and specialty diseases.
Choragon Brevactid (u-hCG)
Choragon Brevactid (u-hCG) is a glycopeptide hormone used to control the timing of ovulation.
It's administered by intramuscular injection, making it a relatively straightforward treatment process. CHORAGON mimics the action of LH, which is a crucial aspect of its mechanism.
This hormone is the drug of choice to trigger ovulation following follicular stimulation and development. It's also used in combination with other medications to stimulate spermatogenesis in male infertility due to hypogonadism.
GONAPEPTYL / DECAPEPTYL* is another medication that's often used in conjunction with CHORAGON, specifically for down regulation of the pituitary before and during controlled ovarian hyperstimulation in assisted reproduction techniques.
Location
Ferring Pharmaceuticals' global headquarters are located in Saint-Prex, Switzerland.

The company has a significant presence in Europe, with manufacturing facilities in several countries.
Ferring has a R&D centre in the Ferring Tower in Ørestad, Copenhagen.
This centre has room for 750 employees in the new building being designed by Foster and Partners.
The company has also built a "center of excellence" in Portugal for its IT services and shared functions.
Ferring B.V., the Dutch subsidiary, expanded to the US in 1980.
The Ferring Research Institute in San Diego, CA, was established in 1996 with a research group that collaborates with academic scientists.
In 2009, the institute moved to a new 38,000-square-foot facility in Sorrento Valley.
Ferring has also built two new facilities in the US and in India.
The company has manufacturing facilities in South America and China.
You might enjoy: BCA Research
Director's Russia Ties
The director of Ferring, Frederik Paulsen, has close ties to Russia. He received the Order of Friendship from Russian president Vladimir Putin in 2008.
Ferring Pharmaceuticals has been accused of disclosing misleading information about several of its products, including Desmopressin and Glypressin. This has led to criticism from consumers.
The nature of Paulsen's visits to Russia has been questioned by Swiss judicial authorities, who are investigating possible bribery in exchange for fiscal arrangements.
The Quiet Company

The Quiet Company is a unique entity that operates with a low profile. It was founded in 2005 by a group of entrepreneurs who wanted to create a business that prioritized sustainability and social responsibility.
The company's headquarters is located in a small town in the countryside, away from the hustle and bustle of city life. This deliberate choice reflects the company's commitment to reducing its carbon footprint.
The Quiet Company has a lean organizational structure, with a flat hierarchy and minimal bureaucracy. This allows for quick decision-making and a high degree of autonomy among employees.
Despite its small size, the company has a strong online presence, with a website and social media channels that showcase its products and values.
See what others are reading: Quiet Logistics
Featured Images: pexels.com


